New Type 1 Gaucher Disease Treatment Approved

3/2/2010
The FDA has approved Shire Human Genetic Therapies’ VPRIV (velaglucerase alfa for injection), a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy in pediatric and adult patients with type 1 Gaucher disease. The approval of VPRIV is important because the supply of the previously approved enzyme replacement therapy (imiglucerase) for Gaucher disease is uncertain and remains disrupted. Patients currently being treated on a stable dose of imiglucerase can be switched to VPRIV and can begin treatment at the same dose.
Clin-eguide™ is an online clinical decision support tool that provides the most accurate evidence-based information for health care providers in the clinical setting. It integrates trusted content from Ovid, Facts & Comparisons®, and Lippincott Williams and Wilkins, as well as other premier publishers.